98%
921
2 minutes
20
The Pediatric Quality Measures Program (PQMP) was established in response to the Children's Health Insurance Program Reauthorization Act of 2009, aiming to measure and improve health care quality and outcomes for the nation's children. This brief report describes the PQMP 2.0 and its components. PQMP 2.0 established a priori research questions (Research Foci) and endeavored to assess usability and feasibility of measures through measure implementation and quality improvement initiatives. The Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare and Medicaid Services (CMS) awarded 6 grants to Centers of Excellence (COEs), and a contract to facilitate collaboration and learning across the COEs. The 6 COEs partnered with stakeholders from multiple levels (eg, state, health plan, hospital, provider, family) to field test real-world implementation and refinement of pediatric quality measures and quality improvement initiatives. The PQMP Learning Collaborative (PQMP-LC) consisted of AHRQ, CMS, the 6 COEs, and L&M Policy Research, LLC. The PQMP-LC completed literature reviews, key informant interviews, and data collection to develop reports to address the Research Foci; aided with development of measure implementation and quality improvement toolkits; conceptualized an implementation science framework, analysis, and roadmap; and facilitated dissemination of learnings and products. The various products are intended to support the uptake of PQMP measures and inform future pediatric measurement and improvement work.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.acap.2021.12.021 | DOI Listing |
J Neurooncol
September 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
Purpose: Cranial irradiation is associated with health-related quality of life (HRQoL) deficits in childhood cancer survivors. We investigated the relationship between radiation dose to brain substructures and HRQoL in children with brain tumors treated with proton beam therapy (PBT).
Methods: Data were obtained from children in the Pediatric Proton/Photon Consortium Registry who received PBT for primary brain tumors between 2015 and 2021.
J Cancer Res Clin Oncol
September 2025
Department of Urology, University Hospital Tübingen, Eberhard Karls University, Hoppe-Seyler Str. 3, 72076, Tübingen, Germany.
Introduction And Objectives: High socioeconomic status (SES) is associated with improved oncological outcomes across various cancer types, including prostate cancer. However, limited evidence exists regarding the impact of SES and lifestyle factors on patient-reported outcomes (PROs), including quality of life (QoL), health status (HS), and functional recovery following radical prostatectomy (RP).
Materials And Methods: We conducted a retrospective single-center analysis of 327 patients undergoing RP (177 open, 150 robotic-assisted) assessing pre- and postoperative functional outcomes (QoL, HS, erectile function, continence).
J Pharm Pharmacol
September 2025
Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Cátedra de Tecnología Farmacéutica II, Universidad de Buenos Aires, C1113AAD Buenos Aires, Argentina.
Objectives: To develop the orphan drug benznidazole (BNZ) in orally disintegrating tablets, for the neglected disease American Trypanosomiasis (Chagas disease) therapy. Although children are highly affected by this disease, there are no specific commercial pharmaceutical preparations for this age group in Argentina and in many other countries.
Methods: In the production process, co-milling in a ball mill was applied to enhance dissolution rates, followed by direct compression.
Pediatr Ann
September 2025
Department of Pediatrics, George Washington University, Washington, DC and.
Routine growth monitoring includes plotting children on World Health Organization or Centers for Disease Control and Prevention charts that have primarily been developed on typical, healthy populations. However, it is advisable to plot children with known genetic conditions on specialized growth curves (SGCs) when they are available. In this review, we highlight the most common genetic conditions for which SGCs are available, clinical reasons to use SGCs based on specific rare diseases, and how these SGCs can be found.
View Article and Find Full Text PDFJ Hosp Palliat Nurs
September 2025
Kimberly A. Pyke-Grimm, PhD, RN, CNS, CPHON, is nurse scientist, Department of Nursing Research and Evidence-Based Practice, Center for Professional Excellence and Inquiry, Stanford Children's Health, Palo Alto, CA, and clinical assistant professor, Department of Pediatrics, Division of Hematology,
Patients undergoing hematopoietic stem cell transplant are at risk for significant morbidity and mortality throughout their treatment course. The aim of this evidence-based practice project was to determine if the use of a palliative care trigger tool impacted the number of palliative care consults and/or the early integration of palliative care services within the pediatric hematopoietic stem cell transplant patient population. A trigger tool was developed to identify patients at highest risk for stem cell transplant-associated morbidity and mortality.
View Article and Find Full Text PDF